Drug Trial Radar · NCT05964790
Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
112
Planned (sponsor's estimate)
Start
Jul 30, 2023
Primary completion
Jun 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10380 relative to placebo for the treatment of participants with schizophrenia.
Conditions
- Schizophrenia
Interventions
HS-10380Drug
Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
PlaceboDrug
Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation cohorts: Incidence and severity of adverse events(AE) ,serious AEs and AE leading to withdrawal from treatment.Time frame: Baseline to Day 43
- Dose escalation cohorts: Changes from baseline in complete blood count (CBC).Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in urinalysis.Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in blood biochemistry test.Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in coagulation function test.Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in thyroid function test.Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in serum prolactin.Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in blood pressure (BP).Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in pulse rate.Time frame: Baseline to Day 36
- Dose escalation cohorts: Changes from baseline in body temperature.Time frame: Baseline to Day 36
- Dose escalation cohorts: Change from baseline in body weightTime frame: Baseline to Day 29
- Dose escalation cohorts: Change from baseline in Electrocardiogram (ECG)Time frame: Baseline to Day 36
- Dose escalation cohorts: Change from baseline in Simpson-Angus Scale (SAS)Time frame: Baseline to Day 36
- Change from baseline in Abnormal Involuntary Movement Scale (AIMS)Time frame: Baseline to Day 36
- Dose escalation cohorts: Change from baseline in Barnes Akathisia Rating ScaleTime frame: Baseline to Day 36
- Dose escalation cohorts: Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline to Day 36
- Expansion cohorts: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)Time frame: Baseline to Day 28
- Expansion cohorts: Positive and Negative Syndrome Scale (PANSS) Response at Week 4, Defined as a 20% or Greater Improvement from Baseline in PANSS Total ScoreTime frame: Baseline to Day 28
- Expansion cohorts: Change from Baseline in Clinical Global Impression-Severity (CGI-S)Time frame: Baseline to Day 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.